Customer input drives Cellomics release of new software for High Content Screening
Pittsburgh, PA (June 2, 2005). -- Cellomics is pleased to announce the availability of its yearly software update, HCi™ 2005. HCi 2005 is available for all ArrayScan® (3.1/4.0, x.5) HCS Reader, KineticScan® HCS Reader and vHCS™ Discovery ToolBox platforms. HCi 2005 adds numerous updates and enhancements to Cellomics’ software applications. With the main focus on ease-of-use, improvements have been made to visualization and analysis, multi-user support, improved speed and robustness of data management. These software enhancements improve user productivity by addressing key ”pain” points in HCS workflow and respond to input from Cellomics’ large customer base.
Commenting on the release, Jeffrey R. Haskins, Ph.D., VP of Technology and Product Development at Cellomics said “With the continued adoption of HCS throughout the drug discovery and academic research community we continue to receive valuable feedback regarding how we could improve our products; we’ve listened closely and HCi 2005 is the result.” Customers will receive many useful features that they’ve asked for, such as improved multi-user protocol management, easy links between visualization and analysis, usability improvements and enhancements to data management. In addition, HCi 2005 deploys our new informatics infrastructure to support the optional, HCS Gateway™ product that brings the power of Cellomics’ HCi software platform to licensed third party HCS instruments. In response to the increasing interest in live-cell kinetic measurements, especially from predictive toxicology and systems biology groups, Cellomics has significantly enhanced the biological utility of the KineticScan HCS Reader by incorporating their complete portfolio of V2 BioApplication image analysis software on this instrument. This enables users with a common set of image analysis tools for both kinetic and fixed endpoint measurements resulting in considerable productivity and efficiency gains. “We are delighted by the valuable and expansive customer input that has driven our development of HCi 2005 to directly address their HCS needs. HCi 2005 is provided at no charge to all customers who are currently under warranty or have coverage via maintenance and support contracts. This builds on Cellomics’ ethos of constant, active improvement of our HCS technology to improve customer productivity” remarked Dan Calvo, President and CEO of Cellomics. About Cellomics Cellomics, Inc. is automating drug discovery through a unique, cell-based assay platform that addresses the needs of Drug Discovery and Systems Biology groups by offering complete systems for High Content Screening (HCS). The platform includes HCS instrumentation (both fixed end-point and kinetic systems), informatics, cellular image analysis software (BioApplications), fluorescent reagents, kits, cell lines, and multiparametric assays. When applied to early drug discovery, this platform is proving to reduce the 'idea-to-discovery' cycle time in drug discovery, while increasing the probability of the therapeutic success of leads as well as enhancing throughput in systems biology and basic research. Cellomics’ proprietary platforms, including the ArrayScanand KineticScanHCS Readers, along with BioApplications software and High Content Informatics (HCi) suite, are in use at multiple sites within all of the top fifteen pharmaceutical companies, as well as leading pharmaceutical and biotechnology companies and academic centers globally. For more information about Cellomics, visit our website at www.cellomics.com.
For further information, contact:
Judy P. Masucci, Ph.D. Director of Marketing Cellomics, Inc. 100 Technology Drive Pittsburgh, PA 15219 412-770-2200 x 2353 412-770-2450 (fax)
http://www.cellomics.com
Upcoming Events
December 13, 2008 ASCB 2008 Please visit our booth at the 49th Annual Meeting of the American Society for Cell Biology ...
Home 
Customer input drives Cellomics release of new software for High Content Screening
top